ADPT
NASDAQAdaptive Biotechnologies Corporation
Price$26.25+0.76 (+2.98%)
01:30 PM07:45 PM
News · 26 weeks84-11%
2026-03-012026-08-23
Mix3290d
- Insider18(56%)
- SEC Filings8(25%)
- Other4(13%)
- Earnings2(6%)
Latest news
25 items- INSIDERDirector Hershberg Robert exercised 15,000 shares at a strike of $6.32 and sold $748,208 worth of shares (30,664 units at $24.40), decreasing direct ownership by 25% to 46,683 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERCEO and Chairman Robins Chad M exercised 600,000 shares at a strike of $6.55 and sold $14,882,166 worth of shares (600,000 units at $24.80) (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERDirector Neupert Peter M sold $3,135,850 worth of shares (124,690 units at $25.15) and exercised 15,000 shares at a strike of $6.32, decreasing direct ownership by 46% to 130,625 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- SECSEC Form 144 filed by Adaptive Biotechnologies Corporation144 - Adaptive Biotechnologies Corp (0001478320) (Subject)
- SECSEC Form 144 filed by Adaptive Biotechnologies Corporation144 - Adaptive Biotechnologies Corp (0001478320) (Subject)
- INSIDERChief Commercial Officer, MRD Bobulsky Susan sold $75,000 worth of shares (3,000 units at $25.00) as part of a pre-agreed trading plan, decreasing direct ownership by 0.75% to 396,989 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- SECSEC Form 10-Q filed by Adaptive Biotechnologies Corporation10-Q - Adaptive Biotechnologies Corp (0001478320) (Filer)
- INSIDERChief Commercial Officer, MRD Bobulsky Susan sold $31,176 worth of shares (1,299 units at $24.00) as part of a pre-agreed trading plan, decreasing direct ownership by 0.32% to 399,989 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- SECAdaptive Biotechnologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits8-K - Adaptive Biotechnologies Corp (0001478320) (Filer)
- PRAdaptive Biotechnologies Reports Second Quarter 2026 Financial ResultsSEATTLE, July 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2026. "We delivered an exceptional second quarter, driven by expanding growth and profitability in MRD, including both our clinical and biopharma businesses," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "The combination of our operating performance, fortified balance sheet and plan to separate the Immune
- INSIDERChief Scientific Officer Robins Harlan S exercised 284,800 shares at a strike of $6.55 and sold $10,780,409 worth of shares (492,400 units at $21.89) as part of a pre-agreed trading plan, decreasing direct ownership by 20% to 812,058 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERChief Commercial Officer, MRD Bobulsky Susan sold $115,000 worth of shares (5,000 units at $23.00) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 401,288 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERChief People Officer Lo Francis exercised 105,762 shares at a strike of $8.91 and sold $2,389,164 worth of shares (105,762 units at $22.59) as part of a pre-agreed trading plan (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- PRAdaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026SEATTLE, July 09, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2026 after market close on Wednesday, July 29, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hou
- INSIDERChief Scientific Officer Robins Harlan S sold $8,501,149 worth of shares (386,240 units at $22.01) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 1,019,658 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERChief People Officer Lo Francis exercised 75,621 shares at a strike of $8.75 and sold $2,157,683 worth of shares (95,842 units at $22.51) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 230,713 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERChief Commercial Officer, MRD Bobulsky Susan sold $10,714 worth of shares (487 units at $22.00) as part of a pre-agreed trading plan, decreasing direct ownership by 0.12% to 406,288 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERChief Commercial Ofc Imm Med Benzeno Sharon exercised 114,329 shares at a strike of $7.75 and sold $3,503,510 worth of shares (165,802 units at $21.13) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 221,278 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERChief Commercial Officer, MRD Bobulsky Susan sold $102,500 worth of shares (5,000 units at $20.50) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 406,775 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERDirector Griffin Michelle Renee exercised 52,084 shares at a strike of $7.80 and sold $1,051,055 worth of shares (52,084 units at $20.18) as part of a pre-agreed trading plan (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- SECSEC Form 144 filed by Adaptive Biotechnologies Corporation144 - Adaptive Biotechnologies Corp (0001478320) (Subject)
- SECAdaptive Biotechnologies Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities8-K - Adaptive Biotechnologies Corp (0001478320) (Filer)
- INSIDERChief Scientific Officer Robins Harlan S sold $1,847,942 worth of shares (106,160 units at $17.41) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 1,405,898 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- PRAdaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes OfferingProceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibilityAdditional proceeds used to pay for the capped call with a premium of 100% and to repurchase $25 million of common stock to reduce potential dilutionRemaining capital to be used for general corporate purposes and opportunistic initiatives in the MRD business SEATTLE, June 17, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT) today announced the pricing of its offering of $300 million aggregate principal amount of 0% convertible senior notes due 2031 (the "notes") in a private offering to persons reasonably believed to be qualified
- INSIDERChief Commercial Officer, MRD Bobulsky Susan sold $95,000 worth of shares (5,000 units at $19.00) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 411,775 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
ADPT FAQ
7 questionsWhat does Adaptive Biotechnologies Corporation do?
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and...Where does ADPT stock trade?
Adaptive Biotechnologies Corporation (ADPT) is listed on NASDAQ.What sector and industry is ADPT in?
Adaptive Biotechnologies Corporation operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Adaptive Biotechnologies Corporation go public?
Adaptive Biotechnologies Corporation (ADPT) completed its IPO in 2019.What are analysts saying about ADPT?
Adaptive Biotechnologies Corporation has had 8 recent analyst actions on file. The most recent action was from Morgan Stanley: Equal-Weight with a $2100.00 price target on 2025-12-02. Recent price targets range from $800.00 to $2100.00.What companies are similar to ADPT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare ADPT side-by-side with any of them on Quantisnow.How can I track ADPT on Quantisnow?
Quantisnow aggregates Adaptive Biotechnologies Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ADPT to receive live email and push alerts on every new disclosure.